Last $66.16 USD
Change Today -0.98 / -1.46%
Volume 361.5K
CBST On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
NASDAQ GS
As of 8:10 PM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

cubist pharmaceuticals inc (CBST) Snapshot

Open
$67.28
Previous Close
$67.14
Day High
$67.80
Day Low
$65.60
52 Week High
02/28/14 - $82.12
52 Week Low
07/23/14 - $58.50
Market Cap
5.0B
Average Volume 10 Days
459.5K
EPS TTM
$0.82
Shares Outstanding
75.7M
EX-Date
--
P/E TM
80.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for CUBIST PHARMACEUTICALS INC (CBST)

cubist pharmaceuticals inc (CBST) Related Businessweek News

View More BusinessWeek News

cubist pharmaceuticals inc (CBST) Details

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. The company offers CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD); and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. It also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozane/tazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, the company develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts.

873 Employees
Last Reported Date: 02/25/14
Founded in 1992

cubist pharmaceuticals inc (CBST) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $750.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $358.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $475.0K
Senior Vice President and General Manager of ...
Total Annual Compensation: $440.2K
Compensation as of Fiscal Year 2013.

cubist pharmaceuticals inc (CBST) Key Developments

Cubist to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy

Cubist Pharmaceuticals Inc. announced that it will present new data at the 54(th) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9 in Washington, D.C. Data highlighted will offer insights into Cubist's commitment to identifying treatments for drug-resistant Gram-positive and Gram-negative bacteria that cause serious infections. Noteworthy presentations will include data on SIVEXTRO(TM) (tedizolid phosphate), recently approved by the United States Food and Drug Administration (FDA) for acute bacterial skin and skin structure infections (ABSSSI), and data on the company's investigational antibiotic ceftolozane/tazobactam. Ceftolozane/tazobactam is under review by the U.S. Food and Drug Administration for the treatment of complicated urinary tract infections and complicated intra-abdominal infections and has an FDA action date of December 21, 2014.

Cubist Pharmaceuticals, Inc. Announces Availability of Bacterial Skin Structure Infection Drug

Cubist Pharmaceuticals Inc., has announced the availability of SIVEXTRO indicated for the treatment of adult acute bacterial skin and skin structure infections, or ABSSSI, as once-daily I.V. and oral formulations. Approved by the FDA on June 20, 2014, SIVEXTRO addresses ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)- which has been categorized by the US Centers for Disease Control and Prevention (CDC) as a serious public health threat. Clinical studies are also ongoing for the potential use of SIVEXTRO in the treatment of hospital-acquired bacterial pneumonia (HABP) /ventilator-associated bacterial pneumonia (VABP).

Cubist Pharmaceuticals Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 10:30 AM

Cubist Pharmaceuticals Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 10:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Michael W. Bonney, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBST:US $66.16 USD -0.98

CBST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.56 EUR -0.07
Nektar Therapeutics $13.53 USD -0.30
Salix Pharmaceuticals Ltd $148.72 USD +5.29
Synergy Health PLC 1,466 GBp -14.00
Theravance Inc $18.46 USD -0.46
View Industry Companies
 

Industry Analysis

CBST

Industry Average

Valuation CBST Industry Range
Price/Earnings 100.0x
Price/Sales 4.5x
Price/Book 3.4x
Price/Cash Flow 608.2x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUBIST PHARMACEUTICALS INC, please visit www.cubist.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.